Mindset Pharma leading the charge to advance psychedelic medicines to treat mental illness
The company is developing intellectual property in two areas it believes are going to be the...
Maxim's analysts said: "Mindset is making progress across its families of next-gen psychedelic...
As one of the first psychedelic companies to go public, the firm’s network of ketamine clinics...
Investors are getting excited about next generation psychedelics that aim to deliver better...
The company is enrolling patients in a Phase 3 clinical trial to evaluate Bucillamine in...
Deep dive
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo tell Proactive that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay. Araujo and Lanthier...
Industry & services
